Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/05/2015 > 197 patent applications in 139 patent subcategories.

20150038400 - Compositions, the preparation and use thereof: The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for... Agent: Kci Licensing, Inc.

20150038401 - Carrier for targeting nerve cells: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or... Agent: Syntaxin Limited

20150038402 - Modulators of protease activated receptors: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder,... Agent:

20150038403 - Compounds that bind to the erythropoietin receptor: The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin.... Agent:

20150038404 - Macrocyclic compounds: This invention relates to novel macrocyclic compounds (e.g., those delineated in the formulae herein), pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially... Agent:

20150038405 - Pharmaceutical composition for preventing or treating arteriosclerosis: The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and... Agent:

20150038406 - Pharmaceutical formulations of tranexamic acid and their use: The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration.... Agent:

20150038407 - Oligopeptide compounds and uses thereof: The present invention relates to novel agents, pharmaceutical compositions containing them, and theft use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO: 40 which have surprisingly been shown to have inhibitory effects on the growth and/or... Agent:

20150038408 - Polypeptides for treating and/or limiting influenza infection: The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic... Agent:

20150038409 - Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta: The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience... Agent:

20150038410 - Heterocyclic nitrogen containing polymer coated analyte monitoring device and methods of use: The present invention is directed to membranes composed of heterocyclic nitrogen groups, such as vinylpyridine and to electrochemical sensors equipped with such membranes. The membranes are useful in limiting the diffusion of an analyte to a working electrode in an electrochemical sensor so that the sensor does not saturate and/or... Agent:

20150038411 - Relaxin for treating patients afflicted of impaired glucose tolerance: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of... Agent: Immundiagnostik Ag

20150038412 - Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor: This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor.... Agent:

20150038413 - Long-acting polypeptides and methods of producing and administering same: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.... Agent: Opko Biologics Ltd.

20150038414 - Organic compounds: A pharmacutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.... Agent: Novartis Ag

20150038415 - Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent: Process for the manufacturing of a drug delivery system based on a polymer comprising dispersed bioactive agent via the following process steps: (a) dissolving a polymer in an organic solvent (b) mixing the dissolved polymer with the bioactive agent (c) laminating the mixture between two polymer sheets, whereby at least... Agent:

20150038417 - Glp-1 agonists: A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist.... Agent: Novo Nordisk A/s

20150038416 - Novel glp-1 receptor modulators: m

20150038418 - Natriuretic peptide compositions and methods of preparation: Therapeutic compositions containing natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing... Agent: Medtronic, Inc.

20150038419 - Simukunin: The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin... Agent: University Of Georgia Research Foundation, Inc.

20150038420 - Methods for treating properdin-related diseases or disorders: The present invention relates to methods for treating or preventing a properd related disease or disorder in a subject in need thereof, or for reducing mortality of a subject suffering from a properdin-related disease or disorder, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a... Agent: The Medicines Company

20150038421 - Factor viii compositions and methods of making and using same: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.... Agent:

20150038422 - Unit dosage forms of pharmaceutical compositions comprising a polymer-factor viii polypeptide conjugate: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.... Agent:

20150038425 - Collagen-binding synthetic peptidoglycans for use in vascular intervention: This invention relates to collagen-binding synthetic peptidoglycans. More particularly, this invention relates to collagen-binding synthetic peptidoglycans for use in vascular intervention procedures. The invention also relates to kits comprising such collagen—binding synthetic peptidoglycans and catheters or stents.... Agent:

20150038423 - Delivery of therapeutic agents by a collagen binding protein: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist... Agent:

20150038424 - Formulations and kits for forming bioadhesive matrices: A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive... Agent: Technology Innovation Momentum Fund (israel) Limited Partnership

20150038426 - Monomeric and dimeric forms of adiponectin receptor fragments and methods of use: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, disclosed herein are methods of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of... Agent:

20150038427 - Collagen-binding synthetic peptidoglycans for wound healing: Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient.... Agent:

20150038428 - Organogels and emulsions for biological and non-biological applications: The present invention relates to organogels and emulsions based on ultrasmall self-assembling peptides. It further relates to methods for producing such organogels and emulsions as well as to the use of the organogels and emulsions in biological and non-biological applications.... Agent:

20150038429 - Etoposide and doxorubicin conjugates for drug delivery: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood... Agent:

20150038430 - Therapeutic peptidomimetic macrocycles: The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.... Agent:

20150038431 - Inflammatory eye disorders: Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye... Agent:

20150038433 - Clusterin pharmaceuticals and treatment methods using the same: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry... Agent: University Of Southern California

20150038432 - Compositions and methods for the treatment of retinal degeneration: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2α, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2α and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to... Agent: Universite De Strasbourg

20150038434 - Melanocortin-1 receptor-specific cyclic peptides: e

20150038435 - N-terminally modified oligopeptides and uses thereof: The present invention is related to N-terminally fatty acid modified peptides or oligopeptides and pharmaceutical compositions comprising such.... Agent:

20150038436 - Tailored glycopolymers as anticoagulant heparin mimetics: The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.... Agent:

20150038437 - Antibacterial compounds and methods for use: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.... Agent: Ptc Therapeutics, Inc.

20150038438 - Antibacterial compounds and methods for use: The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.... Agent:

20150038439 - Method for preparing suspensions of low-solubility materials: A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing... Agent:

20150038440 - Dihydrofuran azetidine derivatives as antiparasitic agents: This invention recites dihydrofuran substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. The substituents A, R1a, R1b, R1c, R2, R3, R4, R6, and n are as described herein.... Agent:

20150038441 - Kit-in-parts for cleaning and treating ears of companion animals: The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of... Agent: Boehringer Ingelheim Vetmedica Gmbh

20150038442 - Polyelectrolyte complexes comprising natamycine and/or phosphite for biocide enhancement: The invention relates to a composition comprising a polyelectrolyte complex of a polyanion and a polycation, further comprising at least one biocide comprising natamycin and/or phosphite. A preferred composition comprises lignosulfonate and chitosan, preferably in relative amount of from 1:2 to 60:1 (w/w). The invention further relates to methods for... Agent:

20150038443 - Transcription factor inhibitors and related compositions, formulations and methods: The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general... Agent: The Ohio State University

20150038444 - Treating myelodysplastic syndromes using lenalidomide: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.... Agent:

20150038552 - Esophageal microrna expression profiles in eosinophilic esophagitis: Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or... Agent:

20150038554 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single... Agent:

20150038555 - Extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single... Agent:

20150038549 - Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity: Compositions and methods for downmodulating expression of target nucleic acids are disclosed.... Agent:

20150038548 - Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases: Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in treating cancer, tumorigenesis and hyper-proliferative disorders.... Agent:

20150038551 - Pharmaceutical composition for preventing or treating diabetes containing tenc1 expression or activity suppressor: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which... Agent: Postech Academy-industry Foundation

20150038550 - Targeting micrornas for metabolic disorders: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the... Agent:

20150038553 - Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent:

20150038556 - Cftr mrna compositions and related methods and uses: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.... Agent:

20150038560 - Methods and compositions for treating neuropathies: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective... Agent: Washington University

20150038557 - Methods and compositions for treatment of retinal degenerative diseases: The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor... Agent:

20150038561 - Mitochondrial targeted rna expression system and use thereof: Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20150038562 - Modified l-nucleic acid: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.... Agent:

20150038559 - Pharmaceutical composition and method for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis: A pharmaceutical composition and method for therapy of neurodegenerative diseases including amyotrophic lateral sclerosis, the composition comprising an adenoviral vector, expressing a human angiogenesis factor gene; an effective amount of the adenoviral vector in the form of a non-replicating nanoparticle based on a genome of human adenovirus type 5 with... Agent:

20150038558 - Rna containing modified nucleosides and methods of use thereof: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also... Agent:

20150038448 - Combination, kit and method of reducing intraocular pressure: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under... Agent:

20150038446 - Compositions and methods for treating retinal degradation: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.... Agent:

20150038445 - Methods and compositions for treating pain: The disclosure provides a new use of adenosine analogs for the treatment of pain through activation of neurokinin 1 (NK1) receptor signaling pathway, thereby inducing the activation of M-type potassium channel to induce outward currents. A method and pharmaceutical composition for treating pain comprising an adenonsine analog that activates NK1... Agent: Academia Sinica

20150038447 - Organ protection, preservation and recovery: This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition... Agent:

20150038449 - Maintenance of platelet inhibition during antiplatelet therapy: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who... Agent: The Medicines Company

20150038450 - Combination therapy for the treatment of cancer: Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for... Agent:

20150038451 - Substituted nucleotide analogs: Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.... Agent:

20150038452 - Methods of treating optic disorders: The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream... Agent:

20150038453 - Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can... Agent: N.v. Nutricia

20150038454 - Antimicrobial compositions and methods of use: Compositions comprising an antimicrobial effective concentration of sucralose and methods of using for treating pharyngeal and other bacterial conditions.... Agent:

20150038455 - Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity: The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.... Agent:

20150038456 - Stable hydrogel compositions including additives: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.... Agent:

20150038457 - Composition comprising hyaluronic acid and mepivacaine: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging... Agent: Teoxane

20150038459 - Protein containing food stuffs: Nutritious protein-containing foodstuffs can be prepared in the form of gels, including protein gel and fruit purees that contain all essential amino acids. A protein gel for use as a foodstuff is prepared by heating an aqueous protein solution to between 160 and 185 degrees Fahrenheit at an acidic pH... Agent:

20150038458 - Skin-protecting alkalinity-controlling composition and the use thereof: A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of... Agent:

20150038460 - 6,5-heterocyclic propargylic alcohol compounds and uses therefor: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease... Agent: Genentech, Inc.

20150038461 - Thiopyrimidinecarboxamides as cxcr1/2 modulators: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCR1/2 inhibitor useful for treating a variety of inflammatory and neoplastic disorders.... Agent: Syntrix Biosystems, Inc.

20150038463 - Compositions and methods to treat cardiac diseases: Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba(bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life... Agent:

20150038462 - Oligonucleotide analog and method for treating flavivirus infections: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of... Agent: Sarepta Therapeutics, Inc.

20150038464 - Methods of increasing light responsiveness in a subject with retinal degeneration: Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting... Agent: The United States Government As Represented By The Department Of Veterans Affairs

20150038465 - Use of derivative compounds of1,3-benzodioxole in insecticidal compositions: The invention relates to the use of a derivative compound of 1,3-benzodioxole of formula (I) wherein R is a linear or branched (C4-C10) alkyl substituent as a synergistic compound of insecticidal active ingredients insecticidal compositions comprising at least one compound of Formula (I) and at least one insecticidal active ingredient... Agent: Endura S.p.a.

20150038466 - Pain relief compounds: The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds.... Agent:

20150038468 - Estrogen antagonists as treatments for sclerosing disorders: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.... Agent:

20150038467 - Pharmaceutical compositions containing phosphatidylserine and curcumin: The present invention describes and claims stable pharmaceutical compositions and/or food supplements based on phosphatidylserine (PS) and curcumin, which are consequently devoid of degradation products, for use in the prevention and treatment of disorders associated with brain aging, and in the prevention and treatment of osteoporosis and/or osteoarthritis.... Agent: Fidia Farmaceutici S.p.a.

20150038469 - Compositions for treatment of cardiometabolic disorders: The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins.... Agent: Neptune Technologies & Bioressources, Inc.

20150038470 - Biocide compositions: Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas.... Agent:

20150038471 - Process for preventing or mitigating biofouling: Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some embodiments, may also inhibit biofouling.... Agent: Baker Hughes Incorporated

20150038472 - Use of therapeutically effective lipids and method for producing organ-/tissue-specific therapeutically effective lipids: The use of therapeutically active lipids for organ/tissue-specific enrichment for the treatment of inflammatory, ischemic or degenerative disorders and/or for stimulating a regeneration is arranged and developed such that the lipids are bound on application to carrier molecules for which cell-specific uptake systems in the cells of the organs and/or... Agent:

20150038474 - Organic compounds: Optionally substituted 3-(thio, sulfinyl or sulfonyl)-7,8-dihydro-(1H or 2H)-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or a substituted 3-(thio, sulfinyl or sulfonyl)-7,8,9-trihydro-(1H or 2H)-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent:

20150038473 - Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories: Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions.... Agent: Foresight Biotherapeutics, Inc.

20150038475 - Testosterone undecanoate compositions: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such... Agent:

20150038476 - Method for treating gynecological diseases: The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical... Agent: Preglem Sa

20150038477 - Orally administrable gallium compositions and methods of use: Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium... Agent:

20150038478 - Beta-lactamase inhibitors: Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of... Agent:

20150038479 - Isoxazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150038480 - Compounds that modulate autoimmunity and methods of using the same: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical... Agent: The Regents Of The University Of Colorado, A Body Corporate

20150038482 - Isoxazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150038483 - Aromatic 5-membered heterocyclic derivative having trpv4-inhibiting activity: x

20150038484 - Indole and indazole compounds that activate ampk:

20150038481 - Pyrimidine compounds for the treatment of cancer: Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents... Agent:

20150038485 - Heterocyclyl aminoimidazopyridazines: The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a... Agent: Bayer Intellectual Property Gmbh

20150038486 - Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.... Agent:

20150038487 - Methods of treating hypertrophic cardiomyopathy: o

20150038489 - Compound and methods for treating long qt syndrome: Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker... Agent: Gilead Sciences, Inc.

20150038488 - Syk inhibitors: s

20150038490 - Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck Sharp & Dohme Corp.

20150038491 - Solid ivabradine-containing composition: The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition.... Agent: Ratiopharm Gmbh

20150038492 - Benzamides and nicotinamides as syk modulators: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods... Agent:

20150038493 - Compounds that trap alpha-oxoaldehydes and alpha-beta-unsaturated aldehydes, meta-compounds containing such compounds, and use of said compounds in treating illnesses related to the accumulation of ages and ales: The present invention relates to a series of molecules derived from 2,3-diaminopropionic acid (DAP), comprising or not comprising an 8-hydroxyquinoline (8-HQ) motif, and to the use of said molecules for trapping an alpha-oxoaldehyde resulting particularly from the degradation of the glucose or for trapping an alpha-beta-unsaturated aldehyde, resulting particularly from... Agent:

20150038494 - Thiazolopyrimidine modulators as immunosuppressive agents: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present... Agent: Katholieke Universiteit Leuven, K.u.leuven R&d

20150038495 - Therapeutic agent for pain: e

20150038496 - Methods and pharmaceutical compositions for the treatment of th2 mediated diseases: The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.... Agent:

20150038497 - Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting... Agent:

20150038499 - Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects: Methods of improving patient safety and reducing undesirable side effects for patients considering therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. In particular, a method of treating a disease in a patient in need of such treatment is provided. The method comprises testing the patient for... Agent:

20150038498 - Thrombin inhibitors: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein Q is CH2, NR4, O, S, S(O) or S(O2), wherein R4 is H, C1-6 alkyl, aryl, or C3-8 cycloalkyl; R1 is a heterocycle or —(CR5R6)1-2NH2,... Agent:

20150038501 - Inhibitors of hcv ns5a: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.... Agent:

20150038500 - Pharmaceutical composition for preventing and treating ophthalmic disorders: The invention relates to a pharmaceutical composition for preventing or treating an ophthalmologic disease comprising a compound of formula (1) as defined in the specification, or a pharmaceutically acceptable salt or isomer thereof as an active ingredient. Also, the invention relates to a composition for cleansing or preserving a contact... Agent:

20150038502 - Isoxazolopyridine orexin receptor antagonists: The present invention is directed to isoxazolopyndine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the isoxazolopyndine compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is... Agent:

20150038506 - Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation... Agent: University Of Basel

20150038503 - Derivatives of 6-substituted triazolopyridazines as rev-erb agonists: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.... Agent: Genfit

20150038504 - Formulation of syk inhibitors: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof.... Agent:

20150038505 - Polymorph of syk inhibitors:

20150038507 - Antiprotozoal compounds: The invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering... Agent:

20150038508 - Treatment of lupus nephritis using laquinimod: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject... Agent: Teva Pharmaceutical Industries, Ltd.

20150038509 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4... Agent:

20150038510 - Cinnoline derivatives: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use... Agent:

20150038511 - Treatment of immune-related and inflammatory diseases: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.... Agent:

20150038512 - Compositions and methods comprising a biocidal polyamine: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity... Agent:

20150038513 - Association between n-hydroxy-4-benzamide and folfox: m

20150038514 - Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents: The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use... Agent:

20150038515 - Inhibitors of hepatitis b virus convalently closed circular dna formation and their method of use: Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.... Agent:

20150038517 - Indole derivative modulators of the alpha 7 nachr: a

20150038516 - Inhibitors of protein kinases:

20150038518 - Methods for the treatment of solid tumors: Described herein are combinations of ACK inhibitors and HDAC inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.... Agent:

20150038519 - Organic compounds: The invention provides a new method of treating diseases or conditions characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, depression, and cognitive impairment of schizophrenia, comprising administering an effective amount of a 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one to a patient in need thereof.... Agent:

20150038520 - Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer: The invention relates to methods for determining the clinical outcome of patients suffering lung cancer and being under treatment with an EGFR inhibitor. The methods are based on the detection of the presence of mutations in the EGFR gene conferring resistance to inhibitors of the EGFR tyrosine kinase activity, wherein... Agent: Pangaea Biotech S.l.

20150038521 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors: e

20150038522 - Combined anticancer drug sensitivity-determining marker: The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance... Agent: Kabushiki Kaisha Yakult Honsha

20150038523 - Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3: The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids,... Agent: Hoffmann-la Roche Inc.

20150038524 - Crystalline naloxol-peg conjugate: Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.... Agent: Astrazeneca Intellectual Property

20150038525 - Novel methysergide derivatives: Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such... Agent: Map Pharmaceuticals, Inc.

20150038526 - Fluorine-containing 5-[2-(pyrid-3-yl)-ethyl]-2,3,4-tetrahydro-1h-pyrido[4,3-b]indoles as agents for reducing uncontrolled protein aggregation: o

20150038527 - Furopyridine derivatives:

20150038528 - 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.... Agent:

20150038529 - Crystalline forms of a prolyl hydroxylase inhibitor: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.... Agent:

20150038530 - Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.... Agent:

20150038531 - Use of a novel aminopyridine derivative to prevent or treat cancer: In Formula 1: X1 and X2 are each independently selected from the group consisting of carbon and nitrogen; R1 to R5 are each independently selected from the group consisting of a hydrogen, a straight, a branched, or cyclo alkyl of C1-C4, a halogen, and a hydroxyl; and R6 is a... Agent:

20150038532 - Pharmaceutical composition of a potent hcv inhibitor for oral administration: A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration.... Agent: Boehringer Ingelheim International Gmbh

20150038533 - Phacetoperane for the treatment of attention-deficit hyperactivity disorder: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method... Agent:

20150038534 - Compounds and methods: e

20150038535 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20150038536 - Tyrosine kinase inhibitors: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or... Agent:

20150038537 - Agents for the control of parasites on animals: The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or... Agent: Hansen-ab Gmbh

20150038538 - Thiadiazolidinediones as gsk-3 inhibitors: The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is... Agent: Asd Therapeutics Partners LLC

20150038539 - Method of increasing the extent of absorption of tizanidine: An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.... Agent: Acorda Therapeutics, Inc.

20150038540 - Instantly wettable oral film dosage form without surfactant or polyalcohol: An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the... Agent: Intelgenx Corp.

20150038541 - Composition and methods for cell modulation: Composition and methods for affecting cell proliferation, metabolism or sensitization, including the potentiation of proteasome inhibitor therapy for the treatment of disease caused by deregulation of ubiquitin-proteasome systems, in a cell or subject. The composition includes a compound in combination with a ubiquitin-proteasome inhibitor. In one embodiment, the compound has... Agent: Aposignal Bioscience LLC

20150038542 - Uses of selective inhibitors of hdac8 and treatment of inflammatory conditions: Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of... Agent:

20150038543 - Anti-glycation properties of oxindole derivatives: This invention provides a series of new oxindole derivatives 1-21, evaluated for their antiglycation potential by using in vitro BSA-MG glycation model. These derivatives showed a varying degree of antiglycation activity with IC50 values ranging between 150-856 μM. Compound 14 (IC50=150.4±2.5 μM) was found to be the most potent among... Agent:

20150038544 - Animal feed composition: Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof... Agent:

20150038545 - Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof: as well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases... Agent: Ikerchem, S.l.

20150038546 - Substituted chroman compounds as calcium sensing receptor modulators: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods... Agent:

20150038547 - Biological basis of adult wellness: This disclosure is of a lowered absorption of nutrients within the adult digestive tract, more specifically, a decreased mechanical absorption of certain specific amino acids over time; said decreased nutritional uptake decreasing wellness of the individual by the mechanism of depletion of bodily reserves; said lowered uptake being mitigated by... Agent:

20150038563 - Stable composition comprising an anti-ageing compound and a solvent: A cosmetic composition including diacetylresveratryl thioctate and a solvent. The solvent has a h value less than or equal to 8 and a d value greater than or equal to 16.9. Also, the use of the abovementioned composition to prevent and/or combat skin ageing.... Agent: Chanel Parfums Beaute

20150038564 - Solid state forms of cabazitaxel and processes for preparation thereof: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.... Agent:

20150038565 - Long acting compositions: The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterised in that the composition includes a non-aqueous carrier and a solvent system comprising castor oil and at least one cyclic... Agent:

20150038566 - Regulation of cholesterol homeostasis: The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal... Agent: University Of Notre Dame Du Lac

20150038567 - Cannabinoid carboxylic acids, salts of cannabinoid carboxylic acids, and the production and uses of same: The invention relates to a compound selected from the group consisting of all stereoisomers and their mixtures of the compounds of general formulas (1)-(4), in which R1 is a straight-chained, branched or cyclic hydrocarbon group with up to 12 C-atoms and X+ is selected from the group consisting of H+,... Agent: The Health Concept Gmbh

20150038569 - Anti-cervical cancer compound and method of use thereof: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall... Agent:

20150038568 - Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis: A pharmaceutic composition for treating an allergic skin disorder. It has an active component and a carrier. The active component has a major active ingredient osthol and a group of minor active ingredients: xanthotoxol, xanthotoxin, isopimpinellin, bergapten, and imperatorine. The major active ingredient osthol accounts for at least 90% by... Agent:

20150038572 - Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy: A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to... Agent:

20150038573 - Anti-obesity agent comprising compound containing benzotropolone ring: According to the present invention, a safe and palatable anti-obesity agent can be provided by incorporating a benzotropolone ring-containing compound which has tea-derived, high inhibitory activities against lipase and alfa-glucosidase. The anti-obesity agent of the present invention does not compromise the flavor of foods and beverage, has palatability, and can... Agent: Suntory Holdings Limited

20150038571 - Antiviral composition against flavivirus: The present invention relates to a composition having antiviral activity for prophylaxis or treatment of flavivirus infection or a disease resulting therefrom in humans or animals, characterised in that said composition consisting of baicalein, or analogues, or derivatives thereof. The composition may further comprise a pharmaceutically acceptable carrier. The antiviral... Agent:

20150038570 - Compositions and products containing s-equol, and methods for their making: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in... Agent: Australian Health & Nutrition Association Limited

20150038574 - Opsin-binding ligands, compositions and methods of use: Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or... Agent: Bikam Pharmaceuticals, Inc.

20150038576 - Compositions and their use for smoking cessation and other treatments: A composition includes a liquid. The liquid aerosolizes for delivery to a user by an airway. The liquid includes an agent that activates a TRPV3 channel. The agent includes a terpenoid compound.... Agent: Sentiens, LLC

20150038575 - Melanogenesis-inhibitory constituents of ligusticum sinense: Melanogenesis-inhibitory constituents of Ligusticum sinense are disclosed. The melanogenesis-inhibitory constituents can be compound I, II, or III having the chemical structures as follow, respectively.... Agent:

20150038577 - N-acetyl l-cysteine chelates and methods for making and using the same: A nutritional supplement for a human, the supplement having a chelate comprised of an N-acetyl-L-cysteine ligand bonded to a metal to form a chelate ring. A method for preparing a chelate comprised of N-acetyl-L-cysteine ligand and a metal having the steps of: dissolving an amount of N-acetyl-L-cysteine in an aqueous... Agent:

20150038578 - Methods and apparatuses for surface functionalization and coating of nanocrystals: The present disclosure describes a method and series of compositions for surface functionalization of nanoparticles that eliminates the possibility of ligand loss in alien environments. In particular, the present disclosure provides method and compositions for production of highly-stable surface-functionalized nanorods of noble metals for in-vivo applications as well as use... Agent:

20150038579 - Method for treating eczema: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.... Agent:

20150038580 - Method for treating skin cancer: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.... Agent:

20150038581 - Histone deacetylase inhibitors: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an... Agent: Harvard University & Medical School

20150038582 - Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency: Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered.... Agent: Qlt Inc.

20150038583 - Orodispersible composition comprising polyunsaturated fatty acids without bad odor or taste: An orodispersible composition without bad odor, smell, or taste comprising polyunsaturated fatty acids (PUFA) and a disintegrant. The disintegrant is a solid dispersion comprising mannitol, xylitol, microcrystalline cellulose, crospovidone and dibasic calcium phosphate. A process of preparing the composition and its use as nutritional or dietary supplement for balancing the... Agent:

20150038584 - Materials for disinfection produced by non-thermal plasma: Aspects of the present subject matter are directed to a method comprising contacting an fluid, optionally containing an added organic material, with a non-thermal plasma to form a disinfection composition, wherein the disinfection composition is a liquid, and contacting a surface with the disinfection composition, wherein the surface is at... Agent: Drexel University

20150038585 - Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective rxr agonists: The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.... Agent:

20150038586 - Use of n-acetylcysteine amide in the treatment of penetrating head injury: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury.... Agent:

20150038587 - Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.... Agent:

20150038588 - Compositions and methods of treatment of status epilepticus: The invention provides a method of treating benzodiazepine-resistant status epilepticus in a subject having been exposed to a nerve agent inducing the status epilepticus.... Agent:

20150038589 - Nutritional product comprising a biguanide: The present invention relates to a nutritional product comprising a biguanide in a concentration of 20 to 1600 mg per 100 g, based on total weight of the nutritional product, the nutritional product further comprising at least one dietary component selected from the group of (i) digestible carbohydrates, (ii) amino... Agent:

20150038590 - N-cycloalkyl-n-[(cycloalkenylphenyl)methylene]-(thio)carboxamide derivatives: The present invention relates to fungicidal N-cycloalkyl-N-[(cycloalkenylphenyl)methylene]carboxamide derivatives and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.... Agent:

20150038591 - Compounds, compositions and methods for the treatment of tauopathies: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of tauopathies, such as Alzheimer's disease and Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent:

20150038592 - Stable water-in-oil emulsions with spreadable oils: The invention comprises a cosmetic and/or dermatological preparation based on water-in-oil emulsions, comprising at least two W/O emulsifiers and at least one oil having a spreadability value of more than 600 mm2/10 min.... Agent:

20150038593 - Disaggregation of aggregated nanodiamond clusters: The present invention is directed to methods of disaggregating nanodiamond clusters, especially those clusters typically produced from detonation syntheses, the nanodiamond particles and dispersions produced from these disaggregation processes, and compositions derived from these nanodiamond particles and dispersions.... Agent: Drexel University

20150038594 - Oral dispersible films: Described herein are orodispersible films comprising a film forming hydrophobic polymer, a disintegrant, a plasticizer and a stabilizer.... Agent: Bluepharma

20150038596 - Differential diagnosis of cancer and other conditions based on expression of p63: This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating... Agent:

20150038595 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the... Agent:

  
01/29/2015 > 180 patent applications in 131 patent subcategories.

20150031598 - Nemo binding domain fusion proteins: Novel fusion proteins compromising nuclear factor kB essential modulator-binding (NEMO) domain or a fragment thereof and MCoTI-I/II or a fragment thereof, and their use for the treatment of inflammatory diseases and other medical conditions.... Agent:

20150031599 - Hemoglobin compositions: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue or red blood cells with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the... Agent:

20150031601 - Antimicrobial peptide variants and polynucleotides encoding same: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.... Agent: Addenium Biotech Aps

20150031600 - Designed biosurfactants, their manufacture, purification and use: The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in... Agent: The University Of Queensland

20150031602 - Compounds: and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkyl). and the alkyl or cycloalkyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two... Agent: Novacta Biosystems Limited

20150031603 - Macrocyclic compounds for suppressing replication of hepatitis c virus: A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.... Agent:

20150031604 - Cyclic polypeptides for the treatment of heart failure: or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention... Agent: Novartis Ag

20150031605 - Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each... Agent:

20150031606 - Compositions comprising a delivery agent and preparation thereof: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.... Agent:

20150031608 - Lipid construct for delivery of insulin to a mammal: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with... Agent:

20150031609 - Methods and compositions for delivering peptides: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting... Agent:

20150031607 - Water-soluble aie luminogens for monitoring and retardation of fibrillation of amyloid proteins: Compounds that exhibit aggregation induced emission (AIE), and more particularly to water-soluble conjugated polyene compounds that exhibit aggregation induced emission. The conjugated polyene compounds can be used as bioprobes for DNA detection, G-quadruplex identification, and potassium-ion sensing. The polyenes also can be utilized as an external fluorescent marker to study... Agent: The Hong Kong University Of Science And Technology

20150031610 - Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins: Described herein are compositions comprising a derivatized polyglucosamine and a small molecule, peptide, or protein and related methods of use, e.g., to deliver a small molecule, peptide, or protein to cells (e.g., cancer cells) or tissues (e.g., mucosal membrane and epithelial membrane), e.g., to treat a disease or condition in... Agent:

20150031612 - Allosteric modulators of egfr and constitutively active mutants: The present invention includes a novel class of allosteric modulators that target a protein having a juxtamembrane segment. In another embodiment, the allosteric modulator is a peptide mimetic that is capable of interacting with an α-helix or a coiled coil domain of a protein. In one embodiment, the peptide mimetic... Agent:

20150031611 - Highly stabilized epidermal growth factor mutants: There are provided mutants prepared by changing a DNA base sequence and an amino acid sequence of an epidermal growth factor (EGF), in which a mutant EGF protein has excellent thermal stability and stability even in the state of an aqueous solution, and a gene encoding the protein are provided;... Agent: Pnp Biopharm Co., Ltd.

20150031614 - Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor: The invention provides methods and compositions for use of desmopressin in combination with a 5-alpha reductase inhibitor. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.... Agent:

20150031613 - Methods and compositions comprising desmopressin in combination wtih a beta-3-adrenergic receptor agonist: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.... Agent:

20150031615 - Growth hormone releasing peptides: e

20150031616 - Use of relaxin to treat placental syndromes: The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy.... Agent:

20150031617 - Use of thymosin alpha for treatment of purulent rhinosinusitis: The present invention provides methods for preventing or treating purulent rhinosinusitis. These methods include administering a composition comprising thymosin alpha 1 to a subject.... Agent:

20150031618 - Muteins of a1m lipocalin and method of production therefor: The present disclosure relates to a collection of novel muteins derived from human α1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a α1m mutein capable of specifically binding to one or more targets other than a target to which wild-type α1m binds. The disclosure... Agent:

20150031619 - Collagen-binding synthetic peptidoglycans, preparation, and methods of use: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates... Agent:

20150031620 - Thrombomodulin variants and use thereof: A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an ammo acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Ala364 and Ala391 of SEQ ID NO: 2. The mutant thrombomodulin has little... Agent:

20150031621 - Method for purification of complement factor h: p

20150031622 - Rhogef12 is a therapeutic target for the treatment of heart failure: The present invention relates to an inhibitor of the Rho guanine nucleotide exchange factor 12 (RhoGEF12) or an inhibitor of an activator of RhoGEF12 for use in the prevention and/or treatment of heart failure associated with cardiac hypertrophy and/or cardiac fibrosis and diseases associated therewith. Further, it relates also a... Agent:

20150031623 - Thrombopoietin receptor ligands for neuroprotection: The present invention provides therapeutic modalities for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in CNS sites by administration of a thrombopoietin receptor ligand.... Agent: Mcw Research Foundation, Inc.

20150031624 - Anti-mesothelin chimeric antigen receptors: The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF)... Agent:

20150031625 - Targeted vectors for cancer immunotherapy: This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided... Agent:

20150031626 - Adam22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease: A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumour sample from the patient for expression of ADAM22, wherein expression of ADAM22 correlates with increased potential for metastasis compared with a... Agent: Royal College Of Surgeons In Ireland

20150031627 - Therapeutically active compounds and their methods of use: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.... Agent: Agios Pharmaceuticals, Inc

20150031628 - Methods and formulations for converting intravenous and injectable drugs into oral dosage forms: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.... Agent:

20150031629 - Ophthalmic formulation derived from silk protein: An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one... Agent: Silktears, Inc.

20150031630 - Peptide pharmaceuticals: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.... Agent:

20150031632 - Orally disintegrating compositions of linaclotide: The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.... Agent:

20150031631 - Pharmaceutical compositions and related methods of delivery: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The... Agent: Chiasma Inc.

20150031633 - Bifunctional peptide: The bifunctional peptide is capable of activating collagen synthesis and inhibiting the production of matrix metallo-proteinases. The peptide has a sequence including three peptide parts A, B and C. The first peptide part A corresponds to a hexapeptide repeated at least three times, the part A being capable of bonding... Agent:

20150031634 - Angiotensin peptides in treating marfan syndrome and related disorders: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically... Agent:

20150031636 - Ibat inhibitors for the treatment of liver diseases: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.... Agent:

20150031637 - Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder: The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (IBAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone;... Agent:

20150031635 - Pharmaceutical compositions with attenuated release of phenolic opioids: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to... Agent:

20150031638 - Low anticoagulant heparins: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and... Agent:

20150031639 - New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents: e

20150031640 - Antibacterial agents: combination of a rifamycin and a switch region inhibitor: It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide... Agent:

20150031641 - Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia: Gene mutations are associated with the progression of acute myeloid leukemia (AML). The invention relates to methods and systems for evaluating the progression of AML based on these gene mutations. The present invention also relates to methods and compositions for treating AML patients by modulating the expression or activity of... Agent: Memorial Sloan-kettering Cancer Center

20150031642 - Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i: The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).... Agent: Boehringer Ingelheim International Gmbh

20150031643 - Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii: The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).... Agent: Boehringer Ingelheim International Gmbh

20150031749 - Biomarker, uses thereof and therapy: A method of determining the Crohn's disease status of a subject comprising the steps of determining the level of miR-29 in a sample from said subject; and comparing the level of miR-29 determined in step (a) with one or more reference values.... Agent: Isis Innovation Limited

20150031743 - Cell transfecting formulations of small interfering rna, related compositions and methods of making and use: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.... Agent: Novartis Vaccines And Diagnostics, Inc.

20150031752 - Coated lipid complexes and their use: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.... Agent:

20150031751 - Compositions and methods for treatment of ovarian cancer: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives... Agent: Rosetta Genomics Ltd.

20150031744 - Method for predicting and detecting tumor metastasis: The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the... Agent:

20150031747 - Methods and compositions for modulating factor vii expression: Disclosed herein are antisense compounds and methods for decreasing Factor VII and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof.... Agent: Isis Pharmaceuticals, Inc.

20150031746 - Methods and compositions for neuroprotection: Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnire's disease.... Agent: Quark Pharmaceuticals, Inc.

20150031748 - Modulating the interaction between zo-2/tjp2 and a snail zinc finger transcription factor family member: There is provided a method of identifying candidate agents capable of modulating interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof.... Agent: Agency For Science, Technology And Research

20150031745 - Nanoconjugates able to cross the blood-brain barrier: The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use.... Agent: Northwestern University

20150031750 - Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent:

20150031742 - Treatment of uterine leiomyomata: Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided.... Agent: The Brigham And Women's Hospital, Inc.

20150031754 - Aptamer modulators of estrogen receptors: The present invention relates to a nucleic acid aptamer molecule that includes a domain that binds to an estrogen receptor, molecular complexes that include the nucleic acid aptamer molecule and an estrogen receptor, and constructed DMA molecules and expression systems, as well as host cells, that the contain an RNA... Agent: Research Foundation Of State University Of New York At Albany

20150031753 - Complexing agents for compositions containing inclusion complexes: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used... Agent: California Institute Of Technology

20150031756 - Lentiviral vectors and uses thereof: The invention relates to compositions containing polynucleotide vectors capable of expressing a nucleic acid encoding a fusion polypeptide on the surface of a viral particle and/or a eukaryotic cell.... Agent:

20150031755 - Nucleic acids specifically binding cgrp: The present invention is related to a nucleic acid molecule capable of binding to CGRP, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′ HWn1n2YGGAn3An4UMn5n6Yn7n8n9n10n11Kn12Rn13ADn14n15 ARn16Un17Cn18n19Un20n21 3′ [SEQ ID NO: 99], wherein H, W, Y, G,... Agent:

20150031757 - Treating glaucoma, cardiovascular diseases, and renal diseases: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular... Agent: Mayo Foundation For Medical Education And Research

20150031644 - Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof: The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.... Agent:

20150031645 - Methods of using human milk oligosaccharides for improving airway respiratory health: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.... Agent: Abbott Laboratories

20150031646 - Carrier enhancing absorption of medication: A carrier enhancing absorption of medication includes a target medication, an emulsifier, a small-molecular hyaluronic acid (HA) component, an absorption enhancer and a cream base, wherein the carrier promotes infiltration of target medication from skin over affected area and enhance the absorption efficacy of human body by synergistic interaction.... Agent:

20150031647 - Taste masked dispersible tablets: The present invention relates to a taste-masked dispersible tablet comprising a drug, a cation exchange resin, and other pharmaceutically acceptable excipients, such that the said drug and the said cation exchange resin are present in an un-complexed form in the tablet. It further relates to a process for the preparation... Agent: Ranbaxy Laboratories Limited

20150031648 - Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them: e

20150031649 - Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps... Agent: Voltarra Pharmaceuticals, Inc.

20150031650 - Ascorbic acid derivative composition and production method of the same, ascorbic acid derivative solution, and skin external preparation: c

20150031651 - Prodrugs of vitamine k: The invention relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.... Agent:

20150031652 - Poly (adp-ribose) polymerase (parp) inhibitors: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and... Agent: Takeda Pharmaceutical Company Limited

20150031653 - Method of treating, delaying and/or preventing alzheimer's disease: The present invention relates to the treatment and/or prevention of Alzheimer's Disease or the symptoms associated therewith by daily administration of a drink formula comprising fresh marine omega-3 oil in an emulsion and resveratrol or derivatives thereof.... Agent:

20150031654 - Natural combination hormone replacement formulations and therapies: Pharmaceutical formulations for co-administering estradiol and progesterone are provided herein. In some embodiments, the formulation comprises solubilized estradiol, suspended progesterone, and a medium chain (C6-C12) oil.... Agent:

20150031655 - Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases: The disclosure provides a method of treating a mammal afflicted with an age-related disorder, comprising administering to the mammal a combination of liver X receptor (LXR) modulator and estrogen receptor (ER) modulator, in an amount effective to treat the mammal. Further disclosed are the LXR modulators and ER modulators used... Agent: University Of North Dakota

20150031656 - Combination therapy for treating androgen deficiency: The present invention relates to a combination therapy for elevating testosterone levels in male mammals in which an antiestrogen or pharmaceutically acceptable salt thereof is co-administered to the mammal with an additional therapeutic agent selected from an androgen and an aromatase inhibitor. The invention is also directed to a combination... Agent:

20150031657 - Sterols derivative, and preparation method and purpose thereof: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting... Agent:

20150031658 - Sterols derivative, and preparation method and purpose thereof: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.... Agent:

20150031660 - 1,2,4-oxadiazole and 1,2,4-thiadiazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150031659 - 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150031663 - Phthalanilate compounds and methods of use: The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective... Agent: University Of Notre Dame Du Lac

20150031662 - Useful combinations of monobactam antibiotics with beta-lactamase inhibitors: A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the... Agent:

20150031664 - Novel crystal form of pyrrolidylthiocarbapenem derivative: Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2θ) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are... Agent: Shionogi & Co., Ltd.

20150031666 - 1,2,4-oxadiazole and 1,2,4-thiadiazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150031665 - 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors: β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.... Agent:

20150031669 - Anticancer benzopyrazines via the inhibition of fgfr kinases: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Astex Therapeutics Limited

20150031668 - Chroman derivatives as trpm8 inhibitors: e

20150031670 - Cyclic amides as metap-2 inhibitors: Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.... Agent: Merck Patent Gmbh

20150031672 - Heterocyclic compounds and uses thereof: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.... Agent:

20150031671 - Novel compound useful for the treatment of degenerative and inflammatory diseases: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations,... Agent:

20150031667 - Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and... Agent:

20150031661 - Compounds useful as inhibitors of atr kinase: d

20150031675 - Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with... Agent:

20150031673 - Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them: e

20150031674 - Serine/threonine kinase inhibitors: Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.... Agent: Genentech, Inc.

20150031676 - Substituted benzothienyl-pyrrolotriazines and uses thereof: This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.... Agent: Bayer Intellectual Property Gmbh

20150031677 - Trioxane thioacetal monomers and dimers and methods of use thereof: Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.... Agent: The Johns Hopkins University

20150031678 - Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments: The present invention relates to new substituted pyrazolo[1,5-a]pyridine having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.... Agent: Laboratories Del Dr. Esteve S.a.

20150031679 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent:

20150031680 - Selective estrogen receptor modulators with short half-lives and uses thereof: The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order... Agent: Repros Therapeutics Inc.

20150031681 - Novel 1-substituted indazole derivative: e

20150031682 - Anti-malarial agents: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.... Agent:

20150031683 - Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis: The invention relates to a new use of a known Rho kinase inhibitor, fasudil or a fasudil derivative selected from hydroy-fasudil or dimethylfasudil, in the treatment of amyotrophic lateral sclerosis (ALS).... Agent: Georg-august-universit&#xc4 T G&#xd6 Ttingen Stiftung &#xd6 Ffentlichen Rechts, Universit&#xc4 Tsmedizin

20150031684 - Sweet flavor modifier: The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of modulating the sweet taste of compositions.... Agent:

20150031685 - Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of... Agent: Dr. Reeddy's Laboratories Ltd.

20150031686 - Phenyl-oxazolyl derivatives, preparation method thereof, and related application of the phenyl-oxazolyl derivatives as an impdh inhibitor: Disclosed are phenyl-oxazolyl derivatives having a general formula (I), a preparation method thereof, and an application of the phenyl-oxazolyl derivatives as an inosine monophosphate dehydrogenase (IMPDH) inhibitor.... Agent:

20150031687 - Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection: s

20150031688 - Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ3 integrin antagonist in the same molecule.... Agent:

20150031689 - Peripherally restricted diphenyl purine derivatives: The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.... Agent:

20150031690 - Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.... Agent: Siena Biotech S.p.a

20150031691 - Inhibitors of beta-secretase: e

20150031692 - Substituted pyrano and furanoquinolines, their preparation and use as medicaments: The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.... Agent:

20150031694 - Antimicrobial agents: The invention provides compounds of formula (I): wherein R1-R7 and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.... Agent:

20150031693 - Pak inhibitors for the treatment of fragile x syndrome: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.... Agent: Afraxis Holdings, Inc.

20150031695 - Small molecule compounds for targeting inflammatory conditions: Small molecule compounds for the treatment of inflammatory conditions, and pharmaceutical compositions and methods relating thereto. The compositions may be used for the treatment of conditions such as multiple sclerosis, type 2 diabetes, psoriasis, rheumatoid arthritis, Hashimoto's thyroiditis, and Crohn's disease. In some embodiments, the pharmaceutical composition and methods pertain... Agent:

20150031696 - Cyanoisoquinoline compounds and methods of use thereof: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:... Agent: Fibrogen, Inc.

20150031697 - Method for preventing ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas: Provided herein are methods of preventing skin cancer, where the methods comprise the step of administering an effective amount of at least one Hsp90 inhibitor to a subject at the risk of developing skin cancer, whereby the skin cancer is prevented in the subject.... Agent:

20150031698 - S-triazine compounds, pharmaceutical compositions and methods of using the same: L1, L2, L3, R1, R2, R3, R4, R5a, R5b, and R5c are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, where microbial infection is either a direct cause or... Agent:

20150031700 - Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists: The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing... Agent: Galderma Laboratories Inc.

20150031699 - Treatment of myelodysplastic syndrome: The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS).... Agent: Boehringer Ingelheim International Gmbh

20150031701 - Compositions and methods for preventing and treating mucositis and weight loss: Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.... Agent:

20150031702 - Pi3k inhibitors for treating cough: The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of cough, in particular idiopathic chronic cough, cough variant asthma, cough associated with thoracic tumour or lung cancer, viral and post-viral cough, upper airways cough syndrome (UACS) or post nasal drip cough, and... Agent:

20150031703 - Novel fgfr3 fusion: [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe... Agent: Astellas Pharma Inc.

20150031704 - Methods and compositions for treating peripheral vascular disease: The invention features a method of treating a peripheral vascular disease or a condition associated with a peripheral vascular disease by administering to a subject an effective amount of at least one phosphodiesterase type 5 inhibitor and at least one nitric oxide donor. The invention also features compositions formulated for... Agent:

20150031705 - Ophthalmic formulations including selective alpha 1 antagonists: Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists.... Agent:

20150031706 - Novel compound useful for the treatment of degenerative and inflammatory diseases: A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or... Agent:

20150031707 - Method for preparing nano particles: The present invention relates to a method for manufacturing nano-scale particles of an active material. More particularly, the present invention relates to a method which uniformly mixes a surfactant having an HLB value of 8 or more and a melting point or glass transition temperature of 80° C. or lower... Agent: Bio-synectics Inc.

20150031708 - Modulators of cftr: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.... Agent:

20150031709 - Heteroaryl compounds and methods of use thereof: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.... Agent: Sunovion Pharmaceuticals, Inc.

20150031712 - Therapeutic compositions containing dipyridamole and treatment packs including such compositions and methods for producing same: A treatment pack comprising: (a) multiple doses of a composition containing dipyridamole as an active ingredient; (b) packaging material; and (c) instructions for topical administration of said composition to the anterior segment of the eye to treat an anterior segment eye disorder.... Agent:

20150031710 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.

20150031711 - Use of inhibitors of bruton's tyrosine kinase (btk): Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more... Agent: Pharmacyclics, Inc.

20150031713 - Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators: which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds... Agent:

20150031715 - Integrin antagonist conjugates for targeted delivery to cells expressing vla-4: The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids,... Agent:

20150031714 - Methods and compositions for prevention of allergic reaction: Embodiments of the invention include methods of preventing and/or reducing the risk or severity of an allergic reaction in an individual. In some embodiments, particular small molecules are employed for prevention and/or reduction in the risk or severity of anaphylaxis. In at least particular cases, the small molecules are inhibitors... Agent:

20150031716 - Piperidinone carboxamide azaindane cgrp receptor antagonists: The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these... Agent:

20150031717 - Derivatives of protoberberine biological alkaloids and use of same inhibiting ulcerative colitis: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically... Agent: Institute Of Materia Medica, Chinese Academy Of Medical Sciences

20150031718 - Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the... Agent:

20150031719 - Topical therapy for the treatment of migraines, muscle sprains, muscle spasms, spasticity and related conditions: The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations... Agent:

20150031720 - Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20150031721 - Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof: The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the... Agent:

20150031722 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent:

20150031723 - Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases: A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon,... Agent:

20150031724 - Aqueous liquid preparations and light-stabilized aqueous liquid preparations: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.... Agent:

20150031725 - Compositions and methods for treating cancer: Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases.... Agent:

20150031726 - Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds: Substituted phenylcarbamoyl alkylamino arenes; substituted phenylthiocarbamyl alkylamino arenes; substituted phenylcarbamoyl alkylamino heteroarenes; substituted phenylthiocarbamyl alkylamino heteroarenes; N-substituted aryl, N′-substituted aryl urea compounds; N-substituted aryl, N′-substituted heteroaryl urea compounds; N-substituted aryl, N′-substituted aryl thiourea compounds and N-substituted aryl, N′-substituted heteroaryl thiourea compounds are provided and may find use as androgen receptor... Agent:

20150031727 - Aminoalkyl-substituted n-thienylbenzamide derivative: [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the... Agent: Astellas Pharma Inc.

20150031728 - Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures: Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents... Agent: Omeros Corporation

20150031729 - Low-tack surface anti-microbial coating composition and method of application: A method for trapping and neutralizing or killing microorganisms on a surface includes: applying a low tack coating composition that comprises an antimicrobial agent onto an inanimate surface; in the coating, killing or neutralizing microorganisms encountered on the surface and encountered from the environment after the applying step is performed;... Agent: Arms Pharmaceutical, LLC

20150031730 - Fungicidal 3-[(1,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2-substituted-1,2,4-oxadiazol-5(2h)-one derivatives: The present invention relates to 3-[(1,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2-substituted-1,2,4-oxadiazol-5(2H)-one derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent:

20150031732 - Febuxostat solid dispersion: The present invention provides a solid dispersion of febuxostat, processes for its preparation, pharmaceutical compositions comprising it and its use for the chronic management of hyperuricemia in patients with gout.... Agent: Ranbaxy Laboratories Limited

20150031731 - Polymorph of a pharmaceutical: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.... Agent: Abbvie Inc.

20150031733 - Tetrazolinone compounds and its use: The present invention provides a compound having an excellent efficacy for controlling pests. A tetrazolinone compound of a formula (1): [wherein, R1 represents an C6-C16 aryl group, an C1-C12 alkyl group, a C3-C12 cycloalkyl group or an adamantyl group, etc., which each optionally be substituted; R2 represents a hydrogen atom,... Agent: Sumitomo Chemical Company, Limited

20150031734 - Pharmaceutical composition containing mirabegron: Provided is a mirabegron-containing pharmaceutical composition in which the leakage of mirabegron can be inhibited when the pharmaceutical composition is dispersed in a liquid, and in which the change in pharmacokinetics caused by the presence or absence of food intake is decreased. The pharmaceutical composition comprises an acid addition salt... Agent:

20150031735 - Solid forms of a transthyretin dissociation inhibitor: The present invention relates to solid forms of the N-methyl-D-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.... Agent:

20150031736 - Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease: Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Treatment may involve a single dose of the active ingredient by oral administration.... Agent:

20150031737 - Stabilized controlled-release pharmaceutical composition comprising gliclazide: The present invention provides a stabilized controlled-release pharmaceutical composition comprising gliclazide and sodium citrate as stabilizing agent; and process for the preparation of said pharmaceutical composition.... Agent:

20150031738 - Cyclic compounds and methods of making and using the same: The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a... Agent: University Of Massachusetts

20150031739 - Panobinostat for use in the treatment of hiv-1: The present invention relates to uses and methods involving Panobinostat and HIV-1. In particular relates the present invention to Panobinostat for use in the treatment of HIV-1 and especially latent HIV-1. This is done using a low dosage of Panobinostat which is highly effective in depleting the HIV-1 reservoir.... Agent: Region Midtjylland

20150031741 - Compositions and methods for improving lactation: The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP levels, resulting in the release of calcium from the bone, which improves lactation.... Agent: University Of Cincinnati

20150031740 - Cosmetic composition for stimulating the cellular anti-aging functions of the skin: The use of a compound of general formula (I), where: R1, R2, R3, R4, R5 are identical or different and each represent a hydrogen atom, a halogen atom, a hydroxyl group or an —OR′ radical in which R′ is a straight or branched, saturated or unsaturated C1-C16 hydrocarbon radical, wherein... Agent:

20150031758 - Transition metal complexes of a bis[thiohydrazide amide] compound: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention... Agent:

20150031759 - Analogues of (-)picropodophyllin, synthesis and uses thereof: Compounds, compositions, methods of making, and methods of using analogues of (−)-picropodophyllin, as well as a transgenic animal model and its use for identifying anticancer agents.... Agent:

20150031760 - Pharmaceutical composition for preventing or treating nervous system disorders comprising sulfuretin or pharmaceutically acceptable salt thereof: The present invention relates to a pharmaceutical composition for preventing or treating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof, and a method of using the composition to prevent or treat nervous system disorders. Moreover, the present invention relates to a functional food composition for alleviating... Agent: Research And Business Foundation Sungkyunkwan University

20150031761 - Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis: The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or... Agent:

20150031762 - Antimicrobial formulations with pelargonic acid: An antimicrobial composition for extending the shelf-life of water, feed or feed ingredients, comprising: water, a mixture of CrC18 organic acids, a mixture of CrC24 aldehydes, 5-25 wt. % pelargonic acid, and 5-30 wt. % trans-2-hexenal.... Agent:

20150031763 - Deodorization of peracids: The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short-... Agent:

20150031764 - Sugar ester peracid on site generator and formulator: Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ... Agent:

20150031765 - Treatment of cognitive impairment: The present invention relates to a compound with the core structure of formula (I), or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof, for use in the treatment of cognitive impairment in a mammal. The compound is preferably isosteviol or steviol, or pharmaceutically acceptable salts or esters, solvates, or... Agent:

20150031766 - Surfactant peroxycarboxylic acid compositions: The present invention relates to compositions including surfactant peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism.... Agent:

20150031767 - Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria: Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum lactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic... Agent: Natracine Uk Limited

20150031768 - C-halogen bond formation: Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H... Agent:

20150031769 - Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels: or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol... Agent: Medicinova, Inc.

20150031770 - Pharmaceutical formulations of hdac inhibitors: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition... Agent:

20150031771 - Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin: There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time... Agent: Korea Institute Of Ocean Science And Technology

20150031772 - Adjustable bioactive agent dispersion within a polymeric coating: A coating comprised of a polymeric material and a bioactive agent where the properties of the casting solvent dictate the dispersion of the embedding bioactive agent. In preferred embodiments, controlled release of the bioactive agent is achieved by homogeneous dispersion of the bioactive agent within the coating. A further aspect... Agent:

20150031773 - Pharmaceutical composition for preventing or treating muscle wasting-related disease comprising diaminodiphenylsulfone or pharmaceutically acceptable salt thereof: The present invention relates to a pharmaceutical composition for preventing or treating a muscle wasting-related disease comprising diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a muscle wasting-related disease by... Agent:

20150031774 - Rasagiline orally disintegrating compositions: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant,... Agent: Teva Pharmaceutical Industries, Ltd.

20150031775 - Composition and method for affecting male and female hormone levels: A composition and method for treating infertility and sexual dysfunction of a male or female human by balancing hormone levels of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol in the human. The composition comprises effective amounts of spermine and spermidine, administered at least once daily for a period of at... Agent: Nokomis Research, Inc.

20150031776 - Method of preventing, treating and diagnosing disorders of protein aggregation: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.... Agent:

20150031777 - Mirna fingerprint in the diagnosis of wilms' tumour: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based... Agent: Comprehensive Biomarker Center Gmbh

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20150205: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.5325 seconds

PATENT INFO